Mohn Kristin G-I, Zhou Fan
Influenza Centre, Department of Clinical Science, University of Bergen, Bergen 5021, Norway.
Emergency Care clinic, Haukeland University Hospital, Bergen 5021, Norway.
Vaccines (Basel). 2018 May 26;6(2):32. doi: 10.3390/vaccines6020032.
The influenza virus is one of a few viruses that is capable of rendering an otherwise healthy person acutly bedridden for several days. This impressive knock-out effect, without prodromal symptoms, challenges our immune system. The influenza virus undergoes continuous mutations, escaping our pre-existing immunity and causing epidemics, and its segmented genome is subject to reassortment, resulting in novel viruses with pandemic potential. The personal and socieoeconomic burden from influenza is high. Vaccination is the most cost-effective countermeasure, with several vaccines that are available. The current limitations in vaccine effectivness, combined with the need for yearly updating of vaccine strains, is a driving force for research into developing new and improved influenza vaccines. The lack of public concern about influenza severity, and misleading information concerning vaccine safety contribute to low vaccination coverage even in high-risk groups. The success of future influeza vaccines will depend on an increased public awarness of the disease, and hence, the need for vaccination-aided through improved rapid diagnositics. The vaccines must be safe and broadly acting, with new, measurable correlates of protection and robust post-marketing safety studies, to improve the confidence in influenza vaccines.
流感病毒是少数几种能使原本健康的人突然卧床数日的病毒之一。这种令人印象深刻的击倒效应,且无前驱症状,对我们的免疫系统构成了挑战。流感病毒不断发生变异,逃避我们预先存在的免疫力并引发疫情,其分段基因组会发生重配,产生具有大流行潜力的新型病毒。流感造成的个人和社会经济负担很高。接种疫苗是最具成本效益的应对措施,目前有多种疫苗可供使用。当前疫苗有效性的局限性,再加上需要每年更新疫苗毒株,这是推动研发新型和改进型流感疫苗的动力。公众对流感严重性缺乏关注,以及有关疫苗安全性的误导性信息,导致即使在高危人群中疫苗接种覆盖率也很低。未来流感疫苗的成功将取决于公众对该疾病的认识提高,从而需要通过改进快速诊断来辅助接种疫苗。疫苗必须安全且作用广泛,具有新的、可测量的保护相关指标以及强有力的上市后安全性研究,以增强对流感疫苗的信心。